Related Experiment Video
Updated: Aug 23, 2026

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer
Julien Mazieres1, Biao He, Liang You
1Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA.
Abstract:
Aberrant activation of the Wingless-type (Wnt) signaling pathway is associated with a variety of human cancers, and we recently reported the importance of aberrant Wnt signaling in lung cancer. On the other hand, inhibition of Wnt signaling suppresses growth in numerous cell types. Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist that can bind Wnt in the extracellular space and inhibit Wnt signaling. Recently, down-regulation of WIF-1 has been reported in several human cancers. To discover the mechanism of WIF-1 silencing in lung cancer, we first identified the human WIF-1 promoter and subsequently examined the methylation status in the CpG islands. By using methylation-specific PCR and sequence analysis after bisulfite treatment, we demonstrate here frequent CpG island hypermethylation in the functional WIF-1 promoter region. This hypermethylation correlates with its transcriptional silencing in human lung cancer cell lines. Moreover, treatment with 5-aza-2'-deoxycytidine restores WIF-1 expression. We then studied WIF-1 expression in 18 freshly resected lung cancers, and we show a down-regulation in 15 of them (83%). This silencing also correlates with WIF-1 promoter methylation. Our results suggest that methylation silencing of WIF-1 is a common and likely important mechanism of aberrant activation of the Wnt signaling pathway in lung cancer pathogenesis, raising its therapeutic interest.
Insights
Aberrant Wnt signaling drives lung cancer. Methylation silencing of Wnt Inhibitory Factor-1 (WIF-1) is a key mechanism, offering potential therapeutic targets for lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Aberrant Wingless-type (Wnt) signaling pathway activation is implicated in various human cancers, including lung cancer.
- Wnt Inhibitory Factor-1 (WIF-1) acts as a secreted antagonist, inhibiting Wnt signaling, and its down-regulation is observed in several cancers.
Purpose of the Study:
- To investigate the mechanism of WIF-1 silencing in lung cancer.
- To determine the role of WIF-1 promoter methylation in lung cancer pathogenesis.
Main Methods:
- Identification of the human WIF-1 promoter.
- Analysis of CpG island methylation status using methylation-specific PCR and bisulfite sequencing.
- Assessment of WIF-1 expression in lung cancer cell lines and clinical samples.
- Treatment with 5-aza-2'-deoxycytidine to evaluate WIF-1 expression restoration.
Main Results:
- Frequent CpG island hypermethylation was observed in the functional WIF-1 promoter region of lung cancer cell lines.
- WIF-1 promoter hypermethylation correlated with its transcriptional silencing.
- WIF-1 expression was restored upon treatment with 5-aza-2'-deoxycytidine.
- Down-regulation of WIF-1 was observed in 83% of fresh lung cancer specimens, correlating with promoter methylation.
Conclusions:
- Methylation-mediated silencing of WIF-1 is a common mechanism contributing to aberrant Wnt signaling activation in lung cancer.
- WIF-1 silencing represents a significant factor in lung cancer pathogenesis.
- Targeting WIF-1 methylation could hold therapeutic potential for lung cancer.
Related Concept Videos
Canonical Wnt Signaling Pathway
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Abnormal Proliferation
MicroRNAs